FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss Shire's $30 billion bid for the nascent Baxalta, the promise of Merck's vaccine for Ebola, and the latest corruption allegations against GlaxoSmithKline.
Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected].